Steward Partners Investment Advisory’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Steward Partners Investment Advisory’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,780	Closed	–	–	2832
2019 Q4	$0	Buy	1,780 +840	+89%	+$2.04K	﹤0.01%	2849
2019 Q3	$3K	Hold	940	–	–	﹤0.01%	2398
2019 Q2	$6K	Buy	+940	New	+$3.58K	﹤0.01%	2193
2018 Q4	–	Sell	-936	Closed	-$18K	–	2496
2018 Q3	$18K	Sell	936 -60	-6%	-$1.52K	﹤0.01%	1621
2018 Q2	$32K	Buy	996 +40	+4%	+$1.44K	﹤0.01%	1281
2018 Q1	$35K	Hold	956	–	–	﹤0.01%	1129
2017 Q4	$75K	Buy	+956	New	+$70.7K	0.01%	704

Steward Partners Investment Advisory's MLNT Position: Q1 2020 in Review

Steward Partners Investment Advisory sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 1,780 shares.

Steward Partners Investment Advisory first reported a position in MLNT in Q4 2017 and held it in 7 quarters. The position peaked at $75K in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Steward Partners Investment Advisory reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Steward Partners Investment Advisory sold 1,780 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020.
Steward Partners Investment Advisory first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
Steward Partners Investment Advisory's Melinta Therapeutics, Inc. Common Stock position peaked at $75K in Q4 2017.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2020, filed 29 Apr 2020.